JCM
AKBA icon

Jacobi Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Jacobi Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-187
Closed -$3K – 1244
2020
Q2 		$3K Hold
187
– – ﹤0.01% 978
2020
Q1 		$1K Hold
187
– – ﹤0.01% 1014
2019
Q4 		$1K Buy
+187
New +$889 ﹤0.01% 989

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobi Capital Management's AKBA Position: Q3 2020 in Review

Jacobi Capital Management sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 187 shares — an estimated $3K sold.

Jacobi Capital Management first reported a position in AKBA in Q4 2019 and held it in 3 quarters. The position peaked at $3K in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Jacobi Capital Management reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Jacobi Capital Management sold 187 Akebia Therapeutics shares in Q3 2020, an estimated $3K.
  • Jacobi Capital Management first reported a position in Akebia Therapeutics in Q4 2019 and held it in 3 quarters.
  • Jacobi Capital Management's Akebia Therapeutics position peaked at $3K in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Jacobi Capital Management's 13F filing for Q3 2020, filed 30 Oct 2020.